![](/img/cover-not-exists.png)
L01*Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD):
Cascinu, S., Aprile, G., Pastorelli, D., Pinto, C., Bordonaro, R., Farina, G., Amoroso, D., Bilancia, D., Ciuffreda, L., Sartori, D., Falcone, A., Silvestris, N., Beretta, G.D., Buonadonna, A., SobrerVolume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv344.01
Date:
October, 2015
File:
PDF, 42 KB
english, 2015